Synapse Open Synapse
Tech

Moderna and Merck say their mRNA cancer vaccine cut death, recurrence by 42%

Ars Technica · · 3 min read

Markers released top-line results today after previously reporting the trial succeeded.

Same story elsewhere

Latest from Ars Technica